TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25424810
Drug: rMenB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: rMenB with reduced OMV doses (0, ¼ or ½ the OMV dose)
Study: 25424810
Drug: Half-dose of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose of 4CMenB
Study: 25424810
Drug: Prelicensure formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prelicensure formulation of 4CMenB
Study: 25424810
Drug: 4CMenB (4-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB (4-dose primary/booster series)
Study: 17050578
Drug: Tobramycin 0.3%,
Normalized name: Tobramycin 0.3%, Dexamethasone 0.1% Ophthalmic drops, suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin 0.3%, 1 drop every two hours for 2 days, then four times daily for 5 days
Study: 11382537
Drug: Repetitive transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive transcranial magnetic stimulation (rTMS) consisting of 30 trains of 2‐s duration stimuli (20 Hz, 90% of motor threshold), after 10 daily sessions.
Study: 9264868
Drug: 17 beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 beta‐estradiol (50 micrograms transdermally or 2 mg orally)
Study: 8353409
Drug: Ethinylestradiol 40
Normalized name: Ethinylestradiol 40 microgram and levonorgestrel 75 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinylestradiol 40 micrograms twice daily
Study: 8353409
Drug: Ethinylestradiol 20
Normalized name: Ethinylestradiol 20 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinylestradiol 20 micrograms four times daily
Study: 28283779
Drug: ME-344 10
Normalized name: LIMOSILACTOBACILLUS FERMENTUM ME-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ME-344 10 mg/kg intravenously weekly plus topotecan 4 mg/m2 on days 1, 8, and 15 of a 28 day cycle
Study: 23001292
Drug: alfentanil 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfentanil 20 μg/kg
Study: 12888778
Drug: ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketamine 0.5 mg/kg
Study: 19893466
Drug: Sodium hypochlorite
Normalized name: Sodium hypochlorite
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium hypochlorite with the adjunct of a proteolytic enzyme
Study: 16402229
Drug: Oily calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oily calcium hydroxide suspension (Osteoinductal) applied subgingivally after nonsurgical periodontal therapy
Study: 14766981
Drug: Posttrial infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Posttrial infusion of 0.75 mg of the cholinesterase inhibitor physostigmine
Study: 9234039
Drug: Saline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (1 ml i.v.) administered on 1 day
Study: 28974567
Drug: On-treatment mean
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-treatment mean systolic blood pressure (SBP)
Study: 26288199
Drug: SFC (25/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFC (25/125 mcg) through BAI
Study: 26288199
Drug: SFC (25/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFC (25/125 mcg) through pMDI
Study: 21288053
Drug: Esomeprazole (more
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (more effective acid inhibitor)
Study: 21288053
Drug: Standard PPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard PPI treatment (control)
Study: 11584993
Drug: Azoles and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azoles and other formulations of amphotericin B
Study: 9227167
Drug: Oral hydroxychloroquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hydroxychloroquine (HCQ)
Study: 3117402
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of adriamycin (20 mg/40 ml or 30 mg/30 ml)
Study: 3117402
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of mitomycin C (20 mg/40 ml)
Study: 3117402
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of thio-TEPA (30 mg/30 ml)
Study: 3117402
Drug: Noninstillation treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninstillation treatments with etretinate or tegafur
Study: 25683060
Drug: Neurokinin B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurokinin B (NKB) administration
Study: 25683060
Drug: Vehicle (placebo)
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (placebo) infusion
Study: 21684508
Drug: Aspirin 50
Normalized name: aspirin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 50 mg
Study: 10718778
Drug: Sibrafiban/Ticlopidine/Aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibrafiban/Ticlopidine/Aspirin
Study: 30293295
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg carboprost methylate suppository
Study: 23782001
Drug: vitamins and
Normalized name: multivitamins and iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitamins and minerals (vit&min) treatment (group A; N.274)
Study: 23782001
Drug: calcium/vitamin D3
Normalized name: calcium/vitamin D3 ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: calcium/vitamin D3 treatment (group B; N.278)
Study: 21832831
Drug: Subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunotherapy (SCIT) with birch extract
Study: 21832831
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with birch extract
Study: 17576867
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg BID
Study: 17576867
Drug: Rivaroxaban 30
Normalized name: rivaroxaban 30-Day Starter Pack (42-15 MG Oral Tablets & 9-20 MG Oral Tablets)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 30 mg BID
Study: 18621928
Drug: Rivaroxaban 40
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban 40 mg once daily
Study: 17576867
Drug: Enoxaparin/vitamin K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin/vitamin K antagonist
Study: 14991935
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1 g twice daily for 1 week (Group I)
Study: 14991935
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1 g twice daily for 2 weeks (Group II)
Study: 11458720
Drug: Midazolam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.1 mg/kg b.w.)
Study: 11458720
Drug: Midazolam (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (for treatment of severe agitation)
Study: 9715356
Drug: Cocaine-alcohol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine-alcohol (4 doses of intranasal cocaine 1 mg/kg every 30 min with oral alcohol 1 g/kg)
Study: 9715356
Drug: Cocaine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (4 doses of intranasal cocaine 1 mg/kg every 30 min)
Study: 9715356
Drug: Alcohol (4
Normalized name: POLYVINYL ALCOHOL (40000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (4 doses of oral alcohol 1 g/kg)
Study: 9715356
Drug: Cocaine placebo
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine placebo (4 doses of placebo cocaine)
Study: 9715356
Drug: Alcohol placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol placebo (4 doses of placebo alcohol)
Study: 22639289
Drug: Intensive glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glycemic control (IGC) for almost 24 h after PCI (n = 82; glucose, 80‐140 mg/dl)
Study: 22639289
Drug: Conventional glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glycemic control (CGC; n = 83; glucose, 180‐200 mg/dl)
Study: 20053938
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid and 30 mg iron (Fe30Fol)
Study: 8171949
Drug: Hypnotics (etomidate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnotics (etomidate, midazolam, propofol)
Study: 24172159
Drug: Hypnotics
Normalized name: HYPNOTICS AND SEDATIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnotics
Study: 8171949
Drug: Various hypnotics
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various hypnotics
Study: 27401514
Drug: Telephone-based symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based symptom management (TSM) consisting of cognitive-behavioral and emotion-focused therapy
Study: 22741257
Drug: Surrounding needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surrounding needling of electroacupuncture and hot compress of Chinese medicine
Study: 19027437
Drug: Control (sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (sham therapy or wait-list)
Study: 16050413
Drug: Combined treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatments with selective drugs
Study: 10591711
Drug: Hypericum extract
Normalized name: Hypericum extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum extract (1050 mg, 350 mg three times daily)
Study: 10591711
Drug: Imipramine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (100 mg, 50 mg, 25 mg, and 25 mg daily)
Study: 21364503
Drug: Lidocaine 40
Normalized name: lidocaine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 40 mg
Study: 1283888
Drug: Mexiletine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine (300 mg/day)
Study: 15028073
Drug: Disopyramide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide (300 mg/day)
Study: 27329612
Drug: 600 ml
Normalized name: urinary bag 600 mL-10" MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 ml of glucose beverage (control)
Study: 27329612
Drug: 600 ml
Normalized name: urinary bag 600 mL-10" MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 ml of soft drink
Study: 27329612
Drug: 355 ml
Normalized name: ALCOHOL 141.5 g in 355 mL TOPICAL SPRAY
Approvals — FDA: no, EMA: no, PMDA: no
Description: 355 ml of soft drink
Study: 25007689
Drug: Intrathecal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal fentanyl 25 microg plus 3 ml of 0.5% hyperbaric bupivacaine (Group BF)
Study: 25007689
Drug: Intrathecal tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal tramadol 25 mg plus 3 ml of 0.5% hyperbaric bupivacaine (Group BT)
Study: 10418894
Drug: Simultaneously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneously administered influenza and pneumococcal vaccines
Study: 23800161
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg infusion every 12 h
Study: 23800161
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg infusion followed by continuous infusion at 8 mg/h
Study: 23800161
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg infusion followed by continuous infusion at 4 or 8 mg/h
Study: 21670453
Drug: Palifermin (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palifermin (180 μg/kg) administered before chemoradiotherapy and once weekly for 7 weeks
Study: 11745911
Drug: 375-mg oral
Normalized name: cefaclor 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375-mg oral dose of linezolid (tablets) while fasting
Study: 9417761
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of rhenium‐186 combined with triamcinolonhexacetonid (group 1)
Study: 9417761
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of erbium‐169 combined with triamcinolonhexacetonid (group 3)
Study: 9417761
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of triamcinolonhexacetonid alone (group 4)
Study: 8518353
Drug: Diet B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet B (low calorie daily menus)
Study: 23176879
Drug: Propranolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (10 mg or 20 mg)
Study: 23176879
Drug: Salbutamol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (5 mg nebulized)
Study: 19836153
Drug: 40 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 Gy in 20 twice‐daily fractions (Arm A)
Study: 19836153
Drug: 20 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 Gy in four daily fractions (Arm B)
Study: 8922358
Drug: Glomerular normofiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glomerular normofiltration (GFR 83‐135 ml x min(‐1) x 1.73 m(‐2))
Study: 8922358
Drug: Glomerular hyperfiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glomerular hyperfiltration (GFR >135 ml x min(‐1) x 1.73 m(‐2))
Study: 1319875
Drug: Maalox 70
Normalized name: Maalox
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maalox 70 (antacid)
Study: 17578485
Drug: Domperidone 40
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 40 mg
Study: 6375874
Drug: Domperidone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (all doses)
Study: 31604480
Drug: At least
Normalized name: Lovaza 1000 MG (at least 900 MG) Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: At least Twice Daily (ALTD) screening
Study: 20569031
Drug: Aloe vera
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe vera cream
Study: 17251214
Drug: Oral pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral pregabalin (titrated to 300 mg)
Study: 17251214
Drug: Aprepitant (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (titrated to 320 mg)
Study: 17251214
Drug: Pregabalin +
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin + parecoxib (40 mg)
Study: 17251214
Drug: Aprepitant +
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant + parecoxib (40 mg)
Study: 9603635
Drug: Ceftazidime (10-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (10-30 mg/kg t.i.d. i.v.)
Study: 7802179
Drug: 27 G
Normalized name: SODIUM CHLORIDE 0.027 g in 3 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 27 G Whitacre needle
Study: 16753947
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg melatonin (Melaxen) daily at 22:30 h for 2 weeks
Study: 12042193
Drug: Risperidone plus
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone plus 400 mg/day of celecoxib
Study: 946580
Drug: Intravenous cortisol
Normalized name: Corticool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cortisol (1,000 mg)
Study: 946580
Drug: Intramuscular betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular betamethasone (12.0 mg)
Study: 25110847
Drug: Medication beliefs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication beliefs
Study: 21648282
Drug: Collagen +
Normalized name: Walgreens Ultra Collagen + Vitamin C 2500mg-60mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen + Calcium (G-III, n=22)
Study: 15315591
Drug: Prophylactic antithrombotic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antithrombotic treatment
Study: 9447569
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba special extract EGb 761 (240 mg/day)
Study: 3258200
Drug: Intravenous polymyxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous polymyxin B for 5 days in addition to standard therapy
Study: 25418186
Drug: Tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5 mg (withdrawal)
Study: 25418186
Drug: Tofacitinib 10
Normalized name: tofacitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 10 mg (withdrawal)
Study: 3912182
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 mg)
Study: 3912182
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 mg)
Study: 3903970
Drug: S-carboxy-methyl-L-cysteine, 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-carboxy-methyl-L-cysteine, 750 mg three times daily for three days before examination
Study: 24840511
Drug: sn-2+3 g/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: sn-2+3 g/L OF
Study: 24840511
Drug: sn-2+5 g/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: sn-2+5 g/L OF
Study: 22607546
Drug: Tailored treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored treatment (T)
Study: 19256057
Drug: Antibacterial treatment
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibacterial treatment plus wardenafil (10 mg in the evening)
Study: 19256057
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (fluoroquinolone + wardenafil)
Study: 11192957
Drug: Nebulized fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized fluticasone propionate (1 mg b.d.)
Study: 11192957
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (2 mg kg(‐1) day(‐1) for 4 days then 1 mg kg(‐1) day(‐1) for 3 days)
Study: 9198507
Drug: No fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No fluid or solids for at least four hours before the injection (Group A, 499 cases)
Study: 28510679
Drug: Intra-articular triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular triamcinolone (40 mg every 12 weeks for 2 years)
Study: 26241420
Drug: Placebo (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (200 micrograms folic acid twice a day)
Study: 23810050
Drug: Low‐viscosity light‐cured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐viscosity light‐cured resin infiltration after enamel conditioning with a 15% HCl gel
Study: 21138531
Drug: Transdermal buprenorphine
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Transdermal buprenorphine (20 μg/hr, 144 hr)
Study: 10793606
Drug: Gelofusine 500
Normalized name: Gelofusine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelofusine 500 ml over 15 min
Study: 3993604
Drug: Milk with
Normalized name: BETTERMILK with Glytactin 10PE Powder for Suspension (Orange Creme)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk with thiocyanate concentration of 19 mg/l
Study: 3993604
Drug: Milk with
Normalized name: BETTERMILK with Glytactin 10PE Powder for Suspension (Orange Creme)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk with thiocyanate concentration of 3.6 mg/l
Study: 3993604
Drug: Milk with
Normalized name: BETTERMILK with Glytactin 10PE Powder for Suspension (Orange Creme)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk with iodine concentration of 0.1 mg/l and thiocyanate concentration of 19 mg/l
Study: 3993604
Drug: Milk with
Normalized name: BETTERMILK with Glytactin 10PE Powder for Suspension (Orange Creme)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk with iodine concentration of 0.1 mg/l and thiocyanate concentration of 3.6 mg/l
Study: 19637777
Drug: Triple regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple regimen with vitamin C (20 mg Omeprazol, 1 g amoxicillin, 250 mg clarithromycin plus 250 mg vitamin C twice daily for 2 weeks)
Study: 19637777
Drug: Triple regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple regimen without vitamin C (20 mg Omeprazol, 1 g amoxicillin, and 500 mg clarithromycin twice daily for 2 weeks)
Study: 17605895
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (5 mg daily) and vitamin B complex for 3 months
Study: 16355501
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg alendronate daily
Study: 20490798
Drug: Dexamethasone 5
Normalized name: dexamethasone 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 5 mg/m²/day administered 30 min prior to etoposide infusion
Study: 11436877
Drug: Singleton endocervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Singleton endocervical application of 0.5 mg dinoprostone gel and intramuscular Prostin 15 M (Carboprost Tromethamine) (1 ml/2 h) administered 10 hours later until abortion
Study: 11436877
Drug: Singleton double-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Singleton double-dose endocervical application of 0.5 mg dinoprostone gel and intramuscular Prostin 15 M (Carboprost Tromethamine) (1 ml/2 h) administered 10 hours later until abortion
Study: 25277789
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg misoprostol sublingually after delivery of the newborn
Study: 16459225
Drug: DAG meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAG meal (10 g of DAG oil)
Study: 7556988
Drug: Nicotinamide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide (25 mg/kg body weight for 12 months)
Study: 2025309
Drug: Ibuprofen and
Normalized name: Ibuprofen and Famotidine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen and Alprazolam
Study: 19208305
Drug: Pressor arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressor arm (not specified treatment)
Study: 17558683
Drug: Low-dose gonadotropin-releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose gonadotropin-releasing hormone agonist (buserelin)
Study: 1303630
Drug: Ketorolac 30
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 30 mg administered 6-hourly